6.54  0.27 (4.31%)		03-02 16:00
Open: 5.98 High: 6.69 Volume: 276,090		Pre. Close: 6.27 Low: 5.98 Market Cap: 37(M)

Short term
Mid term
Targets	6-month :	9.25	1-year :	10.8
Resists	First :	7.92	Second :	9.25
Pivot price	6.35
Supports	First :	5.99	Second :	4.8
MAs	MA(5) :	6.48	MA(20) :	6.4
	MA(100) :	4.62	MA(250) :	4.34
MACD	MACD :	0.2	Signal :	0.2
%K %D	K(14,3) :	37.7	D(3) :	40.6
RSI	RSI(14): 56.2
52-week	High :	7.92	Low :	3.2

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ CING ] has closed below upper band by 37.8%. Bollinger Bands are 30.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	6.69 - 6.73	6.73 - 6.76
Low:	5.91 - 5.94	5.94 - 5.97
Close:	6.49 - 6.54	6.54 - 6.59

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Mon, 02 Mar 2026
Cingulate (NASDAQ: CING) vote on 19% share issuance and warrants - Stock Titan

Tue, 24 Feb 2026
CING Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Tue, 10 Feb 2026
Shane Schaffer Buys 6,809 Shares of Cingulate (NASDAQ:CING) Stock - MarketBeat

Tue, 10 Feb 2026
Peter Werth Purchases 19,455 Shares of Cingulate (NASDAQ:CING) Stock - MarketBeat

Sat, 07 Feb 2026
Cingulate Advances Capital Raise with Private Placement Financing - The Globe and Mail

Wed, 28 Jan 2026
Cingulate Signs Multiple Material Agreements - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	7 (M)
Shares Float	7 (M)
Held by Insiders	28.1 (%)
Held by Institutions	6.8 (%)
Shares Short	390 (K)
Shares Short P.Month	324 (K)

EPS	-2.77
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.57
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-106.7 %
Return on Equity (ttm)	-275.9 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-1.63
Sales Per Share	0
EBITDA (p.s.)	-2.69
Qtrly Earnings Growth	0 %
Operating Cash Flow	-18 (M)
Levered Free Cash Flow	-10 (M)

PE Ratio	-2.37
PEG Ratio	0
Price to Book value	11.27
Price to Sales	0
Price to Cash Flow	-2.75

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.